H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on AKOUOS (AKUS – Research Report) today and set a price target of $25.00. The company’s shares closed last Monday at $5.81, close to its 52-week low of $5.30.
According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -17.6% and a 23.8% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AKOUOS with a $25.00 average price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $22.88 and a one-year low of $5.30. Currently, AKOUOS has an average volume of 131.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akouos Inc is a genetic medicine company focused on developing gene therapies that restore, improve, and preserve hearing. The company is involved in developing potential genetic medicines for a variety of inner ear disorders.
Read More on AKUS:
